

AMENDMENTS TO THE CLAIMS:

The following is a complete listing of the claims.

1.-3. (canceled)

4. (currently amended) A kit for diagnosing an autoimmune disease, the kit comprising:

a first antigen selected from the group consisting of a polypeptide having an amino acid sequence ~~homology of 90% or more with~~ indicated by SEQ ID NO:1, SEQ ID NO:4, or SEQ ID NO:5, and a fragment of said polypeptide, wherein said polypeptide or fragment thereof specifically binds with an antibody from an autoimmune disease patient, ~~provided that said first antigen is not bovine HMG-1;~~

a second antigen selected from the group consisting of a polypeptide having an amino acid sequence ~~homology of 80% or more with~~ indicated by SEQ ID NO:2, SEQ ID NO:6, or SEQ ID NO:8, and a fragment of said polypeptide, wherein said polypeptide or fragment thereof specifically binds with an antibody from an autoimmune disease patient, ~~provided that said second antigen is not bovine HMG-2;~~

a first component for detecting a first antigen-antibody complex; and

a second component for detecting a second antigen-antibody complex; wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, human systemic lupus erythematosus, Sjögren's syndrome, Behçet's disease, primary biliary cirrhosis, microscopic polyangitis/polyarteritis nodosa, ulcerative colitis, Crohn's disease and autoimmune hepatitis.

5.-13. (canceled)

14. (currently amended) A diagnostic drug for detecting an antibody of autoimmune diseases, wherein: the drug comprises, as an antigen:

a polypeptide having an amino acid sequence ~~homology of 90% or more with~~ indicated by SEQ ID NO:1, SEQ ID NO:4, or SEQ ID NO:5, or a fragment of said polypeptide, wherein said polypeptide or fragment thereof specifically binds with an antibody from an autoimmune disease patient; or

a polypeptide having an amino acid sequence ~~homology of 80% or more with~~ indicated by SEQ ID NO:2, SEQ ID NO:6, or SEQ ID NO:8, or a fragment of said

Serial No. 09/214,881
Response to Final Office Action Dated June 13, 2003

polypeptide, wherein said polypeptide or fragment thereof specifically binds with an antibody from an autoimmune disease patient;

wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, human systemic lupus erythematosus, Sjögren's syndrome, Behçet's disease, primary biliary cirrhosis, microscopic polyangitis/polyarteritis nodosa, ulcerative colitis, Crohn's disease and autoimmune hepatitis;

~~wherein said antigen is not bovine HMG-1 or bovine HMG-2.~~

15.-18. (canceled)

19. (new) The kit of claim 4, wherein the first antigen is SEQ ID NO:1.
20. (new) The kit of claim 4, wherein the second antigen is SEQ ID NO:2.
21. (new) The kit of claim 4, wherein the first antigen is SEQ ID NO:1, and the second antigen is SEQ ID NO:2.
22. (new) The diagnostic drug of claim 14, wherein the antigen is SEQ ID NO:1.
23. (new) The diagnostic drug of claim 14, wherein the antigen is SEQ ID NO:2.